The HPV-16 E2 protein is a major regulator of viral DNA replication and gene expression. Through interactions with the viral origin binding protein, E1, it localizes E1 to the origin of replication and stimulates the initiation of viral DNA replication. However, several recent reports have described a number of diverse activities of E2 relating to the induction of apoptosis through both p53 dependent and independent mechanisms, and to induction of growth arrest in both the G1 and G2M phases of the cell cycle. Recent studies have also shown that p53 can speci®cally inhibit HPV DNA replication, albeit through an unknown mechanism. Since p53 has been described in the replication centres of Herpes Viruses, Adenovirus and SV40 we decided to investigate whether any of the above activities of E2 may be related to an association with p53. We show, in a series of in vitro assays, speci®c interaction between p53 and HPV-16 E2 via residues in the carboxy terminal half of the E2 protein. Mutational analysis of p53 indicates that sequences in both the DNA binding and oligomerization domains are essential for the interaction, and a mutant of p53 which is unable to bind E2 is also unable to inhibit HPV DNA replication. Finally, using an inducible system of p53 expression we also show that E2 will complex with p53 in vivo. These results raise the intriguing possibility that p53 may also be involved in HPV DNA replication centres, and also provides explanations for some of the diverse activities reported for the HPV E2 proteins.
Introduction
The HPV-16 E2 protein is a major regulator of viral gene expression and DNA replication. The protein has a modular structure comprising a transactivation domain, a¯exible hinge region, and a carboxy terminal domain which is important for dimerization and DNA binding activity (Giri and Yaniv, 1988) . Within the HPV-16 long control region (LCR) there are four speci®c E2 recognition sites, characterized by the sequence ACCGN4CGGT, to which E2 binds as a dimer (Androphy et al., 1987a) . Through interactions at these sites E2 can speci®cally upregulate the viral oncogene expression (Cripe et al., 1987; Bouvard et al., 1994; Kovelman et al., 1996) . Under certain circumstances, when the E2 protein is overexpressed, transcriptional repression is also observed (Bouvard et al., 1994; Steger and Corbach, 1997) . Two of the E2 binding sites in the LCR are located close to the viral origin (ori) of DNA replication (Remm et al., 1992; Lu et al., 1993) . Through its ability to interact with the viral ori binding protein E1, E2 brings about a local concentration of E1 at the ori, and thus stimulates the initiation of viral DNA replication Stenlund, 1995, 1996) . Extensive mutational analyses have now clearly separated the functions of E2 important for transcriptional activation, and for stimulation of viral DNA replication (Sakai et al., 1996; Piccini et al., 1997) .
As well as these obvious virological activities of the E2 protein, there are a number of reports of additional functions of E2. Overexpression of E2 has been reported to induce apoptosis in a number of dierent assay systems. Some of this activity is related to the ability of E2 to repress viral gene expression when it is highly expressed, resulting in a decrease in E6 expression and consequent increased levels of p53 (Desaintes et al., 1997) . However, there are other examples of E2 inducing apoptosis through mechanisms which are still p53 dependent, but are unrelated to its eects on E6 expression (Desaintes et al., 1997) . In addition, E2 has also been shown to induce growth arrest in the G1 phase of the cell cycle (Hwang et al., 1996; Goodwin et al., 1998) , as well as to abrogate the mitotic checkpoint (Frattini et al., 1997) through both p53 dependent and independent mechanisms.
A number of dierent DNA tumour viruses have now been shown to inhibit the activity of the cellular tumour suppressor protein, p53. These inhibitory activities are frequently attained via quite diverse mechanisms. SV40 large T antigen binds and sequesters p53 (Bargonetti et al., 1992) , Adenovirus E1B 55 kd protein binds to, and inactivates, p53 transcriptional activity (Yew et al., 1994) , although recent reports indicate that Adenovirus proteins will also target p53 for degradation (Querido et al., 1997; Steegenga et al., 1998) . The E6 proteins from the high-risk HPV types are normally expressed at very low levels (Androphy et al., 1987b; Banks et al., 1987) and they overcome p53 function by targeting it for rapid proteasome mediated degradation Schener et al., 1990) . Although these viruses have developed elaborate mechanisms for overcoming the growth inhibitory functions of p53, there are now several reports of p53 being found within viral DNA replication centres in infected cells. These were ®rst described for SV40 (Braithwaite et al., 1987; Gannon and Lane, 1987) , but p53 was also subsequently shown to be present in the DNA replication compartments of Herpes simplex (HSV) and also Cytomegalovirus (CMV) infected cells (Wilcock and Lane, 1991; Zhong and Hayward, 1997; Fortunato and Spector, 1998) . p53 has also recently been reported in viral DNA replication centres in Adenovirus infected cells (Konig et al., 1999) . The potential role of p53 in HPV DNA replication has not been extensively addressed, although a recent study showed that p53 could speci®cally inhibit HPV DNA replication (Lepik et al., 1998) . We have been interested in whether p53 may exert this activity by interacting with a component of the HPV DNA replication machinery. Taking into account the pleiotropic activities which have been reported for E2, it was natural to investigate whether or not E2 might interact with p53. We show both in vitro and in vivo that HPV-16 E2 speci®cally interacts with the p53 protein. This interaction requires sequences in the p53 DNA binding and oligomerization domains and sequences within the carboxy terminus of E2. Further, a mutant of p53 which cannot bind E2 is defective in its ability to inhibit viral DNA replication. These results demonstrate that p53 may play a role in HPV DNA replication, and suggest the need for caution in interpreting E2 biological activity in situations of overexpression.
Results

HPV-16 E2 binds p53 through sequences in its carboxy terminus
In order to investigate the possibility of an interaction between HPV-16 E2 and p53, fragments of E2 were expressed in E. coli as GST fusion proteins encoding full length, amino terminal (amino acids 1 ± 138) and carboxy terminal sequences (amino acids 237 ± 365). The GST fusion proteins were puri®ed and their ability to bind p53 was assessed by performing a series of GST pull-down assays with in vitro translated radiolabelled p53. The results obtained are shown in Figure 1 . It is clear that full length HPV-16 E2 retains a signi®cant proportion of the input p53 protein compared with no binding on the GST control. Interestingly, when the binding assay is performed with the amino and carboxy terminal portions of the E2 protein, it shows that all the sequences necessary for binding p53 lie within the carboxy terminal half of the E2 protein. No interaction was observed with the amino terminal sequences of the E2 protein.
To further de®ne the region of E2 responsible for the interaction with p53 a series of truncated GST-E2 fusion proteins were produced. These are shown schematically in Figure 2a . The fusion proteins were again puri®ed, and binding assays were performed with in vitro translated p53; the results obtained are shown in Figure 2b . As can be seen, wild type levels of binding to p53 are seen with the fusion protein containing sequences from 250 ± 351. Further truncations result in a progressive loss of binding to p53 with the 250 ± 307 construct being completely negative. These results indicate that the region of E2 essential for binding to p53 lies predominantly within the sequence 339 ± 351. This region of E2 contains sequences necessary for dimerization but it lies outside the core DNA binding domain of the protein (Prakash et al., 1992; Hedge et al., 1992) .
P53 binding to E2 correlates with its ability to inhibit HPV DNA replication
Having shown that HPV-16 E2 can bind to p53 through a small stretch of amino acids within its carboxy terminal region, we were next interested in de®ning which regions of p53 were necessary for complex formation with E2. To do this, a series of binding assays were performed with GST-E2 fusion protein and mutants of p53 previously shown to be defective in oligomerization (Tarunina and Jenkins, 1993) . The results obtained are shown in Figure 3 . It is clear that wild type p53 is again retained with a high eciency, as is the mutant H175. This is a naturally occurring mutant of p53 and is defective in its ability to bind the consensus DNA recognition sequence. In contrast, the carboxy terminal mutants of p53, defective for oligomerization, were all reduced in their ability to bind E2. The 518 mutant, which only forms dimers, showed weak binding to E2, but the 338 and 1262 mutants, both of which can only exist as monomers, failed to bind to E2. These results indicate that sequences within the carboxy terminus of p53 contribute to the ability of p53 to bind to HPV-16 E2.
To further investigate whether the carboxy terminal sequences of p53 were directly responsible for binding E2 or whether reduced binding was a consequence of the loss of oligomerization, we performed a series of binding assays in which a monomeric mutant of p53 was restored to a dimer through incubation with an amino terminal monoclonal antibody, similar to studies performed previously (Thomas et al., 1996) . GST-E2 fusion protein was puri®ed as above and incubated with either in vitro translated wild type p53 or the monomeric mutant 338. The results obtained are shown in Figure 4 . As can be seen in the presence of preimmune antibody the 338 mutant failed to bind to the GST-E2 fusion protein. In contrast, if the in vitro Figure 1 HPV-16 E2 binds p53 through sequences in its carboxy terminus. HPV-16 E2 was expressed as GST fusion proteins encoding either full length E2 (WT), carboxy terminal sequences from 237 ± 365 (C-T) or amino terminal sequences from 1 ± 138 (N-T), puri®ed and equal amounts used to measure binding to in vitro translated radiolabelled p53. The bound p53 was assessed by PAGE and autoradiography. Input p53 and binding to control GST protein is also shown translated p53 protein was pre-incubated in the presence of pAb1801, which binds sequences within the amino terminal region of p53 (Banks et al., 1986) , the ability of 338 to bind E2 is restored. When the same assay was performed using pAb1802, which binds sequences in the carboxy terminus of p53 that are absent in the 338 mutant (Banks et al., 1986) , no eect on the ability of 338 to bind E2 was observed. These results demonstrate that ecient interaction between E2 and p53 requires p53 oligomerization and, further, that the sequences in the carboxy terminal region of p53 are not directly involved in the association.
Previous studies had shown that the trp248 mutant of p53, which lies close to the H175 mutant used in this study, was defective in its ability to inhibit HPV DNA replication (Lepik et al., 1998) . We therefore investi- Figure 1 using the GST-E2 fusion proteins as indicated. Bound p53 was determined following PAGE and autoradiography and input p53 is also shown Figure 3 Sequences within the carboxy terminus of p53 are required for binding E2. The ability of the indicated mutants of p53 to bind E2 was assessed by performing GST pull-down assays with GST or wild type GST-E2 fusion protein. The bound p53 was determined following PAGE and autoradiography and the inputs of the p53 proteins are shown HPV-16 E2 interaction with p53 P Massimi et al gated the ability of the trp248 mutant to bind HPV-16 E2 and the results obtained are shown in Figure 5 . As can be seen, this mutant is greatly reduced in its ability to interact with HPV-16 E2, when compared to the wild type p53. In addition, the presence of pAb1801 has no stimulatory eect upon its ability to bind E2, thus further demonstrating the speci®city of the results shown in Figure 4 . Having de®ned the regions of p53 which are important for binding E2, we next analysed the capacity of these mutant p53 proteins to inhibit HPV DNA replication in vivo. Human 293 cells were transfected with an HPV-16 ori containing plasmid, together with a plasmid expressing the HPV-16 E1 and E2 proteins plus the dierent p53 mutants. The cells were harvested after 72 h and the amount of replicated plasmid DNA was assessed following DpnI digestion and Southern blot analysis. The results obtained are shown in Figure 6 . In agreement with previous observations, the wild type p53 strongly inhibits HPV DNA replication (Lepik et al., 1998) . Interestingly the trp248 mutation which is defective for E2 binding, is also defective in its ability to inhibit HPV replication. This contrasts with the H175 mutant which binds E2 with wild type ability and is also wild type with respect to its ability to inhibit viral DNA replication. However, the oligomerization defective mutants of p53 were also equally eective at inhibiting HPV DNA replication. This would appear to rule out an involvement of E2 in this activity of p53. Nonetheless, these mutants have all the necessary sequences for binding E2, once they assume a higher order structure (see Figure 4) , which is certainly not the case with the trp248 mutation.
HPV-16 E2 binds p53 in vivo
Having shown that HPV-16 E2 will complex with p53 in vitro, we were next interested in ascertaining whether this interaction could also take place in vivo. To do this we made use of a cell line that constitutively expresses p53, whose function is inducible (Littlewood et al., 1995) . p53 was fused to a mutant form of the oestrogen receptor (ER) and stable cell lines were grown out following drug selection. The function of the p53-ER fusion protein could then be induced following treatment with 4-hydroxy tamoxifen as previously described (Littlewood et al., 1995) . Figure 7a shows the levels of p53 fusion protein expression in uninduced cells and 6 h post induction compared with control transfected Saos-2 cells. Addition of inducer does not signi®cantly aect p53-ER levels over this period of time. We then used these cells to ascertain whether HPV-16 E2 could complex with p53 in vivo. The p53 expressing cells were transfected with a plasmid expressing high levels of HPV-16 E2 (Bouvard et al., 1994) and after 18 h p53 function was induced in some transfectants by the addition of ligand. After a further 6 h the cells were harvested and E2 protein immunoprecipitated with an anti-E2 polyclonal antibody. The precipitates were then Western blotted and co-immunoprecipitated p53 was detected by probing with a pool of anti-p53 monoclonal antibodies (Banks et al., 1986) . The results obtained are shown in Figure 7b . In cells transfected with E2 expression plasmid, no co-immunoprecipitating p53 was seen when the p53 was not induced, nor if the immunoprecipitation was performed with a preimmune antibody. In addition, in the absence of E2 expression plasmid the anti-E2 antibody only coimmunoprecipitated minimal levels of p53 protein. In contrast, in cells which express E2 and in which the p53 protein is induced, a signi®cant amount of p53 is coimmunoprecipitated with the anti E2 antibody. These results demonstrate conclusively that HPV-16 E2 and p53 will indeed form complexes in vivo. Figure 4 p53 oligomerization is essential for binding E2. The ability of wild type p53 (WT) and the 338 mutant to bind GST-E2 was assessed following pre-incubation for 30 min with preimmune antibody (PI) or the p53 speci®c monoclonal antibodies pAb1801 or pAb1802 as indicated: the 338 mutant lacks the 1802 epitope. The bound p53 was determined following PAGE and autoradiography and inputs of the p53 proteins are shown Figure 5 The trp248 mutation abolishes E2 binding. The ability of wild type (WT) and the trp248 (248) mutant to bind GST-E2 was assessed following pre-incubation with preimmune (PI) or the p53 speci®c monoclonal antibodies pAb1801 and pAb1802. The bound p53 was determined following PAGE and autoradiography and inputs of the p53 proteins are shown 
Discussion
The HPV-16 E2 protein is a major regulator of viral gene expression and has a number of additional pleiotropic eects within the cell. These include the induction of apoptosis and growth arrest in G1 and abrogation of the mitotic checkpoint control during the cell cycle. These activities appear to be mediated by both p53 dependent and independent pathways (Hwang et al., 1996; Goodwin et al., 1996; Desaintes et al., 1997; Frattini et al., 1997) . Since p53 has also been reported to speci®cally inhibit HPV DNA replication, we performed a series of studies to investigate any possible associations between E2 and p53. We show in a series of assays, performed both in vitro and in vivo, that HPV-16 E2 and p53 are capable of forming protein ± protein interactions. These results provide a number of possible explanations for the diverse activities reported for the HPV-16 E2 protein.
We ®rst investigated the potential for an E2-p53 interaction using a series of GST-E2 fusion proteins and in vitro translated p53. It is clear that all the sequences within E2 that are necessary for binding p53 lie within the carboxy terminal portion of the protein.
More detailed deletion analysis of the HPV-16 E2 protein de®ned the minimal region responsible for binding p53 as spanning amino acids 339 ± 351, although sequences from 307 ± 339 would also appear to contribute to the interaction. We cannot formally exclude any involvement of the region spanning residues 250 ± 307, but this seems unlikely. Residues 339 ± 351 lie outside the region of E2 which is responsible for DNA binding, and this excludes the possibility that the interaction is mediated via non speci®c interaction through any residual DNA. However, this region of E2 does contain sequences necessary for E2 dimerization and it will be of interest to determine whether this aspect of E2 function is aected in the presence of p53.
Mutational analysis of p53 revealed a number of interesting points. Firstly, mutants which aected p53 oligomerization were also defective for binding E2. In contrast, the DNA binding-defective H175 mutant of p53 retained the ability to bind E2 whereas the trp248 mutant, which is also defective for DNA binding, did not. We therefore compared the ability of these two mutants to inhibit viral DNA replication and found that, whereas the trp248 was defective, and this is in agreement with previous studies (Lepik et al., 1998) , the H175 exhibited wild type levels of activity. Therefore these studies would tend support the hypothesis that p53 inhibits HPV DNA replication through an interaction with the viral E2 protein.
However the oligomerization defective mutants of p53, although defective for binding E2, nonetheless still retain the ability to inhibit viral DNA replication. The most likely explanation for this apparent contradiction comes from the studies which showed that sequences within the carboxy terminal region of p53 are not directly involved in the association with E2. Thus, in a series of studies with the monomeric mutant of p53, 338, which is defective in its ability to bind E2, prior incubation with a monoclonal antibody which induces dimerization, partially restored the ability of this mutant to bind E2. These results suggest, therefore, that p53 oligomerization is essential for complex formation with E2 in vitro, but that the sequences within the p53 protein which are directly involved lie outside this carboxy terminal domain. At present we have no information as to what proportion of the 338 and 1262 mutants of p53 are present in higher order complexes within the cell, suce to say, that previous studies have shown that these mutants are capable of activating target promoter expression (Thomas et al., 1996) , indicating residual ability to form multimeric complexes.
A key aspect in de®ning any protein ± protein interaction is the ability to demonstrate its existence in vivo. To do this we have made use of a novel system, in which p53 expression is constitutive, but its function is inducible. This enables us to attain high levels of p53 expression without obtaining the deleterious eects on cell survival which would normally be encountered. By transfecting a HPV-16 E2 expression plasmid into these cells, followed by immunoprecipation of E2 and p53 detection by Western blotting, we have been able to demonstrate that the E2-p53 association also takes place in vivo. An important aspect of this particular assay was the lack of association between E2 and p53 when the p53 protein function was not induced. In the Saos-2 cells stably expressing an ER-p53 fusion protein were transfected with either an E2 expression plasmid (lanes 3 ± 5) or vector alone (lane 2). After 18 h, the p53 protein was either induced with 4-hydroxytamoxifen (lanes 2 ± 4) for 6 h or left uninduced (lane 5). Cells were then harvested and immunoprecipitated with either anti E2 antibody (lanes 2, 4 and 5) or preimmune antibody (lane 3). Coprecipitated p53 was detected by Western blotting using a pool of anti p53 monoclonal antibodies as probes. Lane 1 shows 10% of the extract used for the immunoprecipitations absence of ligand the p53-ER fusion protein is present as an inactive complex with HSP90 and other polypeptides (Pratt, 1990 for review) . This complex would also not appear to be accessible to the HPV-16 E2 protein, since no signi®cant degree of coimmunoprecipitation was obtained under these conditions. However, upon induction of p53, ecient complex formation with the E2 protein could be detected. These results demonstrate that the E2-p53 interaction also takes place in vivo.
At present the biological signi®cance of the E2-p53 association is unclear. However, it is intriguing to note that p53 has been found in the viral replication centres of SV40, HSV, CMV and Adenovirus (Braithwaite et al., 1987; Gannon and Lane, 1987; Wilcock and Lane, 1991; Zhang and Hayward, 1997; Fortunato and Spector, 1998; Konig et al., 1999) . Whether this represents a means by which p53 is inhibiting viral replication, or whether this represents an actual role for p53 in viral replication remains to be determined. It is interesting to note that a recent report also described HPV DNA replication occurring in very similar nuclear structures to those described for HSV and Adenovirus, although the status of p53 within these complexes was not determined (Swindle et al., 1999) . We tend to favour the hypothesis that some p53 may, in fact, not be deleterious to all viral replication, since in the case of HPV an elaborate mechanism appears to have evolved, involving alternative splicing within the E6 open reading frame which ®ne-tunes the levels of p53 present within the cell (Pim et al., 1997) . Studies are in progress to investigate these aspects further.
The E2-p53 association may also be of relevance for some of the additional known activities of E2, unrelated to viral gene expression and DNA replication. A number of these activities, in particular induction of apoptosis and G1 arrest, have been assigned to pathways which are p53 dependent but which are independent of E2's ability to regulate viral gene expression. Obviously, both the apoptotic and growth arrest pathways are regulated directly by p53 and it is not inconceivable that some of these activities of E2 might be mediated through an association with p53. Considering the importance of p53 in regulating a large number of dierent pathways within the cell, there is an obvious need for caution in interpreting the results of studies in which the E2 proteins are overexpressed.
In conclusion, we have shown a speci®c and ecient interaction between the HPV-16 E2 protein and p53. These data have potentially important implications both for viral pathogenesis and for elucidation of the mechanisms of action of the HPV E2 proteins.
Materials and methods
Cells and transfections
Saos-2 cells were grown in DMEM supplemented with 10% foetal calf serum. Transfections were performed using calcium phosphate precipitation as described previously .
GST fusion protein puri®cation and in vitro binding assays GST fusion protein expression and puri®cation was done as described previously (Thomas et al., 1996) . In vitro translations were performed using the TNT coupled reticulocyte lysate system (Promega). The GST-E2, GST-E2CT and GST-E2NT constructs have been described previously (Piccini et al., 1995) and the series of E2 carboxy terminal trunctions were generated using PCR ampli®cation and were veri®ed by DNA sequencing. The wild type and mutant p53 expression constructs have also been described previously (Tarunina and Jenkins, 1993; Thomas et al., 1996) . Brie¯y, the dimeric mutant 518 has point mutations 373L, 380L and 387L; monomeric mutant 1262 has point mutations 341K, 344E, 348E and 355K and monomeric mutant 338 is truncated at amino acid residue 338. The trp248 mutant was kindly provided by Bert Vogelstein.
Transient DNA replication assay
These were performed in human 293 cells and were processed as described previously (Piccini et al., 1997) .
Generation of p53Arg-ER 4, a cell line constitutively expressing a p53-ER fusion protein
The construct pCDNA3.1 p53Arg-ER was generated by PCR cloning the p53-ER sequences from construct pBabepuro p53ERTM (kind gift of Gerard Evan) and inserting them into the HindIII/EcoRI sites of plasmid pCDNA3.1 zeo (Invitrogen). The new construct contains the open reading frame of wild type p53 (Arginine polymorphism at residue 72) fused to sequences encoding the hormone-binding domain of a mutant murine oestrogen receptor (Danielian et al., 1993) . The construct was transfected into Saos-2 osteosarcoma cells, and the cells placed under Zeocin (Invitrogen) selection. Drug-resistant colonies were picked, grown up and tested for constitutive expression of the p53-ER fusion protein by Western blot analysis. The cell line p53Arg-ER 4 generated by this method constitutively expresses the p53Arg-ER fusion protein, whose function is then inducible by addition of the synthetic ligand, 4-hydroxytamoxifen, to the cell medium at a concentration of 100 nM.
In vivo co-immunoprecipitation
The p53Arg-ER 4 cells were transfected either with pCMV-E2 (Bouvard et al., 1994) or with empty vector. After 18 h cells were either induced or uninduced with 4-hydroxytamoxifen, and proteins extracted as described previously (Thomas et al., 1996) . Extracts were immunoprecipitated with either an anti-E2 polyclonal antibody (Piccini et al. 1997) or preimmune antibody. Precipitates were then subjected to SDS ± PAGE and transferred to nitrocellulose. Co-precipitated p53 was detected by using a pool of the anti-p53 monoclonal antibodies pAb1801, pAb1802 and pAb1803 (Banks et al., 1986) and developed using the Amersham ECL according to the manufacturer's instructions.
